Landos Biopharma Inc (LABP) Annual Income Statement (USD)
LABP Quarterly Financials (USD)
Frequently Asked Questions About Landos Biopharma Inc (LABP) Stock
Landos Biopharma Inc's (LABP) last reported annual revenue was USD 0.00.
Landos Biopharma Inc's (LABP) annual revenue growth rate based on the revenue reported in the past 5 years is : N/A
Landos Biopharma Inc's(LABP) is not profitable as of its last reported annual financials.
The net profit margin for Landos Biopharma Inc's(LABP) from its laster reported year is N/A
The return on equity (ROE) for Landos Biopharma Inc's(LABP) from its last reported annual financials is : -61.86%
The return on assets (ROA) for Landos Biopharma Inc's(LABP) from its last reported annual financials is : -34.11%
The return on invested capital (ROIC) for Landos Biopharma Inc's(LABP) from its last reported annual financials is : -64.09%
The Debt to Equity ratio for Landos Biopharma Inc's(LABP) from its last reported annual financials is : 0.00%
The dividend yield for Landos Biopharma Inc's(LABP) from its laster reported year is 0.00%
Landos Biopharma Inc's(LABP) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for LABP !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
